Pharmaceutical compositions and dosage forms of thalidomide

Details Pharmaceutical compositions and dosage forms of thalidomide Pharmaceutical compositions and dosage forms of thalidomide

2007-06-12

2007-06-12

Krass, Frederick (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S323000, C424S451000

Reexamination Certificate

active

10608077

ABSTRACT:
Pharmaceutical compositions and single unit dosage forms of thalidomide and pharmaceutically acceptable prodrugs, salts, solvates, hydrates, or clathrates are disclosed. Also disclosed are methods of treating and preventing diseases and conditions such as, but not limited to, leprosy, chronic graft-vs-host disease, rheumatoid arthritis, sarcoidosis, an inflammatory condition, inflammatory bowel disease, and cancer using the novel dosage forms disclosed herein.

REFERENCES:
patent: 5385901 (1995-01-01), Kaplan et al.
patent: 5405855 (1995-04-01), Andrulis, Jr. et al.
patent: 5434170 (1995-07-01), Andrulis, Jr. et al.
patent: 5593990 (1997-01-01), D'Amato
patent: 5629327 (1997-05-01), D'Amato
patent: 5643915 (1997-07-01), Andrulis et al.
patent: 5654312 (1997-08-01), Andrulis, Jr. et al.
patent: 5712291 (1998-01-01), D'Amato
patent: 5731325 (1998-03-01), Andrulis, Jr. et al.
patent: 6001828 (1999-12-01), Andrulis, Jr. et al.
patent: 6071948 (2000-06-01), D'Amato
patent: 6114355 (2000-09-01), D'Amato
patent: 6140346 (2000-10-01), Andrulis, Jr. et al.
patent: 6228879 (2001-05-01), Green et al.
patent: 6235756 (2001-05-01), D'Amato
patent: 6469045 (2002-10-01), D'Amato
patent: 6914067 (2005-07-01), Govindarajan et al.
patent: 2003/0191098 (2003-10-01), D'Amato
Baker et al., Efficacy of Thalidomide in the Treatment of Relapsed and Refractory Myeloma, Haematology Society of Australia and New Zealand, Abstracts Jul. 25-28, 2000, 54.
Gennaro, Remington: The Science and Practice of Pharmacy, Mack Publishing Co. 19th, 1618, 1642-1644.
Scheffler et. al., 1999, Clin Pharmacol Ther, 65, 483-490.
Teo et. al, 1999, Journal of Clinical Pharmacology, 39, 1162-1168.
Teo et al., 2000, Biopharmaceutics and Drug Disposition, 21, 33-40.
“Thalomid,”Physician's Desk Reference, 53th Ed., pp. 3457-3462 (1999).
“Thalomid,”Physician's Desk Reference, 54th Ed., pp. 911-916 (2000).
“Thalomid,”Physician's Desk Reference, 55th Ed., pp. 1081-1085 (2001).
“Thalomid,”Physician's Desk Reference, 56th Ed., pp. 1154-1158 (2002).
“Thalomid,”Physician's Desk Reference, 57th Ed., pp. 1153-1157 (2003).
“Thalomid,”Physician's Desk Reference, 58th Ed., pp. 1122-1127 (2004).
“Thalomid,”Physician's Desk Reference, 59th Ed., pp. 1095-1099 (2005).
“Thaildomide,” Printout from www.grunenthal.com/cw/en—EN/html/cw—en—en—aboutus.jhtml?CatId=cw—en—en—aboutus—e—01 (date unknown).
“Getting Thalidomide,” Printout from http://www.4imago.com/mpd/mexico.htm (May 12, 2004).
“Talizer,” Printout from http://216.239.37.104/translate—c?hl=en&sl=es&u=http://wwww.facmed.unam.mx/bmnd/pl (date unknown).
“Sauramide,” Printout from http://www.kodc.or.kr/jaga/suaramide—photo.htm (date unknown).
“Notice Destinee Au Patient,” Notice to Patients regarding Thalidomide Laphal (Date unknown).
“Historical Timeline,” Printout from http://www.pharmion.com/corporateweb/home.nsf/Content/Historical Timeline (date unknown).
“Thalidomide 100 mg Tablets (EntreMed Formulation),” Celgene internal document (date unknown).
“Products,” Printout from http://www.daburpharma.com/htmls/prod—form.html (date unknown).
“Myrin (Thaidomide),” Printout from http://www.lipomed.com/Pharma/myrin/overview/ (date unknown).
“Thalidomide,” The Merck Index, 11thEd., p. 9182 (1989).
“Thalidomide,” The Merck Index, 12thEd., p. 9389 (1996).
“Thalidomide,” The Merck Index, 13thEd., p. 9323 (2001).
Guo et al., “A prototype intelligent hybrid system for hard gelatin capsule formulation development,”Pharmaceutical Technology, pp. 44-60 (Sep. 2002).
Rouhi, “Thalidomide,” Chemical & Engineering News, pp. 122-123 (Jun. 20, 2005).
“Thalidomide,”Drugs of the Future, Entry # 91361 (2005).
Abdel-Razeq et al.,Drugs of the Future, 29(10): 1059-1063(2004).
Sommer,Drugs of the Future, 24(1):67-75 (1999).
“Thalidomide,”Drug Data Report, 17(5):468 (1995).
“Thalidomide,”Drug Data Report, 17(5):482 (1995).
“Thalidomide,”Drug Data Report, 20(11):962 (1998).

Affiliated with

Also associated with

Rating

Pharmaceutical compositions and dosage forms of thalidomide does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical compositions and dosage forms of thalidomide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions and dosage forms of thalidomide will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3857730